$Novo-Nordisk A/S(NVO)$ Bought-To The Moon - Tiger Brokers Online Investing Community - To The Moon

42
5
Favorite

$Novo-Nordisk A/S(NVO)$

Bought more nvo as this sell off is overblown. I believe it's moat is still intact and the new CEO has been working in the company for 32 years and knows it inside out If anyone can turn novo around he can

NVO

08-01 23:20

USNovo-Nordisk A/S

Side	Price \| Filled	Realized P&L
Buy Open	48.00 12	-1.03% Holding

Novo-Nordisk A/S

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

42

Report

Comment（5）

Top
Latest

Trade Feed Decoder
·08-02
Analysis of Novo Nordisk (NVO) trade: The +0.3% gain reflects a precision-oriented entry in a stable pharma stock, likely capitalizing on Novo Nordisk's strong positioning in diabetes/obesity treatments. While the minimal profit suggests tight risk management, it raises questions about the trade's strategic objective – whether targeting short-term momentum or accumulating a core position. The pharmaceutical sector's defensive characteristics align with conservative strategies, but the narrow margin leaves limited room for volatility. Traders might evaluate if this aligns with a scalping approach or serves as a tactical hedge. Given Novo's fundamental strength, the execution demonstrates discipline, though the small gain underscores the importance of scaling decisions in low-volatility blue chips.
Reply
Like
Report
Wade Shaw
·08-02
Long-term play—trusting leadership to drive the turnaround!
Reply
Like
Report
glowzi
·08-02
Great perspective
Reply
Like
Report
Orchid Zin
·08-04
Great article, would you like to share it?
Reply
Like
Report
Asphen
·08-03
brave
Reply
Like
Report

Most Discussed

{"i18n":{"language":"en_US"},"data":{"magic":2,"id":462926698619096,"tweetId":"462926698619096","gmtCreate":1754061667941,"gmtModify":1766092093519,"author":{"id":3571535693267201,"idStr":"3571535693267201","authorId":3571535693267201,"authorIdStr":"3571535693267201","name":"Aaronykc","avatar":"https://static.tigerbbs.com/a6fb0a4f08d4e7b8733e7ebc2445aad5","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":12,"crmLevelSwitch":1,"currentWearingBadge":{"badgeId":"972123088c9646f7b6091ae0662215be-2","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Master Trader","description":"Total number of securities or futures transactions reached 100","bigImgUrl":"https://static.tigerbbs.com/ad22cfbe2d05aa393b18e9226e4b0307","smallImgUrl":"https://static.tigerbbs.com/36702e6ff3ffe46acafee66cc85273ca","grayImgUrl":"https://static.tigerbbs.com/d52eb88fa385cf5abe2616ed63781765","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.07.14","exceedPercentage":"80.77%","individualDisplayEnabled":0},"individualDisplayBadges":[{"badgeId":"9427a906234c4b18a82ec3d7730b7fa8-1","templateUuid":"9427a906234c4b18a82ec3d7730b7fa8","name":"Star Contributor","description":"Published at least 3 PICK posts (or 10 IDEA posts) and, within the past 30 days, posted at least 1 PICK post (or 4 IDEA posts) and 1 comment","bigImgUrl":"https://community-static.tradeup.com/news/1866dcf97a73be1c330f85862546aedc","smallImgUrl":"https://community-static.tradeup.com/news/4f5c5fa8e2c7683bb5a7fce8753ee456","redirectLinkEnabled":1,"redirectLink":"https://ttm.financial/activity/market/2023/star-contributors/","hasAllocated":1,"isWearing":0,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2025.11.25","individualDisplayEnabled":1,"backgroundColor":{"dark":"#675a37","tint":"#f9ebc2"},"fontColor":{"dark":"#ffffff","tint":"#ab7a0e"}}],"fanSize":1240,"starInvestorFlag":true,"fullDisclosureFlag":true,"starInvestorFollowerNum":961,"starInvestorOrderShareNum":389,"userFollowInvestorFlag":false,"orderNotificationFlag":false,"ror":54.52,"showRor":true,"investmentPhilosophy":"Long term investor swing trades for short term gains. Subscribe to see my trades in real time","winRationPercentage":66.929134,"tradeVolumeEst":0},"themes":[],"images":[],"coverImages":[],"html":"<html><head></head><body><a href=\"https://ttm.financial/S/NVO\">$Novo-Nordisk A/S(NVO)$&nbsp;</a><p>Bought more nvo as this sell off is overblown. I believe it's moat is still intact and the new CEO has been working in the company for 32 years and knows it inside out If anyone can turn novo around he can&nbsp;</p></body></html>","htmlText":"<html><head></head><body><a href=\"https://ttm.financial/S/NVO\">$Novo-Nordisk A/S(NVO)$&nbsp;</a><p>Bought more nvo as this sell off is overblown. I believe it's moat is still intact and the new CEO has been working in the company for 32 years and knows it inside out If anyone can turn novo around he can&nbsp;</p></body></html>","text":"$Novo-Nordisk A/S(NVO)$ Bought more nvo as this sell off is overblown. I believe it's moat is still intact and the new CEO has been working in the company for 32 years and knows it inside out If anyone can turn novo around he can","highlighted":1,"essential":1,"paper":1,"likeSize":42,"commentSize":5,"repostSize":90,"favoriteSize":0,"link":"https://ttm.financial/post/462926698619096","repostId":0,"isVote":1,"tweetType":1,"viewCount":6701,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":["NVO"],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":true,"orderData":{"uuid":"3571535693267201","orderId":"39998248564035584","kind":"TRADE","symbol":"NVO","secType":"STK","symbolHtmlTag":"<a href=\"https://ttm.financial/S/NVO\">$Novo-Nordisk A/S(NVO)$&nbsp;</a>","symbolHtmlTagHref":"https://ttm.financial/S/NVO","symbolName":"Novo-Nordisk A/S","market":"US","action":"BUY","currency":"USD","symbolLogo":"https://static.tigerbbs.com/4454e2be594d73a2a7bfa9c42bfb69f7","showFilledQuantity":true,"nameCN":"Novo-Nordisk A/S","orderType":"LMT","filledQuantityFinal":12,"avgFillPrice":48,"createTime":1754061619,"filledQuantity":"12","filledQuantityScale":"0","openFlag":true,"side":"DEBIT","contractMajorDescription":"Novo-Nordisk A/S","contractExtraDescription":"NVO","legs":[],"completedFlag":false,"orderPnl":{"openRealizedPnlPercent":0,"openUnrealizedPnlPercent":-0.0103},"quickOrderFlag":false},"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":["订单分享帖"],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":164,"optionInvolvedFlag":false,"xxTargetLangEnum":"ORIG"},"commentList":[{"id":463008234955344,"commentId":"463008234955344","gmtCreate":1754068838228,"gmtModify":1754069532588,"authorId":10000000000011060,"author":{"id":10000000000011060,"idStr":"10000000000011061","authorId":10000000000011060,"name":"Trade Feed Decoder","avatar":"https://community-static.tradeup.com/news/4dc8fec78bad5acffbf563bdbc6bc8ed","vip":4,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":462926698619096,"objectIdStr":"462926698619096","type":1,"supId":0,"supIdStr":"0","prevId":0,"prevIdStr":"0","content":"Analysis of Novo Nordisk (NVO) trade:  \nThe +0.3% gain reflects a precision-oriented entry in a stable pharma stock, likely capitalizing on Novo Nordisk's strong positioning in diabetes/obesity treatments. While the minimal profit suggests tight risk management, it raises questions about the trade's strategic objective – whether targeting short-term momentum or accumulating a core position. The pharmaceutical sector's defensive characteristics align with conservative strategies, but the narrow margin leaves limited room for volatility. Traders might evaluate if this aligns with a scalping approach or serves as a tactical hedge. Given Novo's fundamental strength, the execution demonstrates discipline, though the small gain underscores the importance of scaling decisions in low-volatility blue chips.","text":"Analysis of Novo Nordisk (NVO) trade:  \nThe +0.3% gain reflects a precision-oriented entry in a stable pharma stock, likely capitalizing on Novo Nordisk's strong positioning in diabetes/obesity treatments. While the minimal profit suggests tight risk management, it raises questions about the trade's strategic objective – whether targeting short-term momentum or accumulating a core position. The pharmaceutical sector's defensive characteristics align with conservative strategies, but the narrow margin leaves limited room for volatility. Traders might evaluate if this aligns with a scalping approach or serves as a tactical hedge. Given Novo's fundamental strength, the execution demonstrates discipline, though the small gain underscores the importance of scaling decisions in low-volatility blue chips.","html":"Analysis of Novo Nordisk (NVO) trade:  \nThe +0.3% gain reflects a precision-oriented entry in a stable pharma stock, likely capitalizing on Novo Nordisk's strong positioning in diabetes/obesity treatments. While the minimal profit suggests tight risk management, it raises questions about the trade's strategic objective – whether targeting short-term momentum or accumulating a core position. The pharmaceutical sector's defensive characteristics align with conservative strategies, but the narrow margin leaves limited room for volatility. Traders might evaluate if this aligns with a scalping approach or serves as a tactical hedge. Given Novo's fundamental strength, the execution demonstrates discipline, though the small gain underscores the importance of scaling decisions in low-volatility blue chips.","likeSize":0,"commentSize":0,"subComments":[],"verified":10,"allocateAmount":0,"commentType":"valid","coins":0,"score":0,"disclaimerFlag":true,"disclaimerType":1,"specialCommentTag":"AI_ANALYSE"},{"id":463328480338016,"commentId":"463328480338016","gmtCreate":1754136348665,"gmtModify":1754136353734,"authorId":10000000000011036,"author":{"id":10000000000011036,"idStr":"10000000000011035","authorId":10000000000011036,"name":"Wade Shaw","avatar":"https://static.tigerbbs.com/a539edbf3388702a82cb1d4728704766","vip":8,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":462926698619096,"objectIdStr":"462926698619096","type":1,"supId":0,"supIdStr":"0","prevId":0,"prevIdStr":"0","content":"Long-term play—trusting leadership to drive the turnaround!","text":"Long-term play—trusting leadership to drive the turnaround!","html":"Long-term play—trusting leadership to drive the turnaround!","likeSize":0,"commentSize":0,"subComments":[],"verified":10,"allocateAmount":0,"commentType":"valid","coins":0,"score":0,"disclaimerType":0},{"id":462991742612112,"commentId":"462991742612112","gmtCreate":1754064531412,"gmtModify":1754291003344,"authorId":9000000000000141,"author":{"id":9000000000000141,"idStr":"9000000000000141","authorId":9000000000000141,"name":"glowzi","avatar":"https://static.tigerbbs.com/1c3f21ebce27a7e369dd15e4a48fc05e","vip":8,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":462926698619096,"objectIdStr":"462926698619096","type":1,"supId":0,"supIdStr":"0","prevId":0,"prevIdStr":"0","content":"Great perspective","text":"Great perspective","html":"Great perspective","likeSize":0,"commentSize":0,"subComments":[],"verified":10,"allocateAmount":0,"commentType":"valid","coins":0,"score":0,"disclaimerType":0},{"id":464042365583624,"commentId":"464042365583624","gmtCreate":1754316665782,"gmtModify":1754316669304,"authorId":4192238401478552,"author":{"id":4192238401478552,"idStr":"4192238401478552","authorId":4192238401478552,"name":"Orchid Zin","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","vip":1,"crmLevel":11,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":462926698619096,"objectIdStr":"462926698619096","type":1,"supId":0,"supIdStr":"0","prevId":0,"prevIdStr":"0","content":"<p>Great article, would you like to share it?</p>","text":"<p>Great article, would you like to share it?</p>","html":"<p>Great article, would you like to share it?</p>","likeSize":0,"commentSize":0,"subComments":[],"verified":10,"allocateAmount":0,"commentType":"invalid","coins":0,"score":0,"disclaimerType":0},{"id":463479840629440,"commentId":"463479840629440","gmtCreate":1754184042701,"gmtModify":1754184049201,"authorId":3576339097425722,"author":{"id":3576339097425722,"idStr":"3576339097425722","authorId":3576339097425722,"name":"Asphen","avatar":"https://community-static.tradeup.com/news/55ff1b64b2787933c17d863ecae83f09","vip":1,"currentWearingBadge":{"badgeId":"1f541396f99840fb977d0ab0ce343c94-1","templateUuid":"1f541396f99840fb977d0ab0ce343c94","name":"Weekly Top Contributor","description":"Contributors with best Editor's Picks every week","bigImgUrl":"https://static.tigerbbs.com/271475ceaf67d40016c8cfa16c08c8b3","smallImgUrl":"https://static.tigerbbs.com/5a6336061b9ba82ba9177c7ec476f5f2","redirectLinkEnabled":0,"redirectLink":"https://ttm.financial/TW/9000980585","hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":2,"allocatedDate":"2022.08.08","individualDisplayEnabled":0,"individualDisplaySort":0,"categoryType":2004},"crmLevel":12,"crmLevelSwitch":1,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":462926698619096,"objectIdStr":"462926698619096","type":1,"supId":0,"supIdStr":"0","prevId":0,"prevIdStr":"0","content":"brave","text":"brave","html":"brave","likeSize":0,"commentSize":0,"subComments":[],"verified":10,"allocateAmount":0,"commentType":"invalid","coins":0,"score":0,"disclaimerType":0}],"hasMoreComment":true,"orderType":2}